IndustryCompany release

Viatris raises 2026 guidance midpoints as RYZUMVI wins FDA nod for presbyopia

🇺🇸 Viatris Inc (VTRS) · Thu 05 Nov 2026

Viatris reported third-quarter revenue of $3.75bn and a GAAP net loss, citing a US approval, a Japanese approval and a product launch.

Viatris reported third-quarter 2026 results on 5 November, with revenue of $3.75bn, described as flat. The company posted a GAAP net loss of $325m and adjusted EBITDA of $1.20bn. It raised the midpoints of its 2026 guidance.

On the regulatory front, the company noted that the US Food and Drug Administration has approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for adult presbyopia, the age-related decline in near vision. Viatris also noted that WAKIX has been approved in Japan.

In commercial news, Viatris said it launched the Gwyn Lo contraceptive patch in the US in October. It also expects to complete its planned acquisition of Pacira BioSciences by the end of November.

The information comes from the company's results announcement. The summary available does not provide further detail on indications, labelling or financial drivers behind the quarter.

What it means for your team

  • RYZUMVI's US approval for adult presbyopia adds a new ophthalmic product to the FDA-approved landscape. Teams tracking ophthalmology should watch for labelling and launch details.
  • WAKIX's approval in Japan extends its regulatory footprint to a further major market. Local post-approval obligations will follow.
  • Viatris expects the Pacira BioSciences acquisition to close by the end of November. Quality, PV and market-access teams linked to either company should expect integration planning to follow completion.

Company's press release (SEC filing): Viatris Inc ↗

Article written by VigiEye from the official source (Viatris Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →